NCT05760248 is a Phase 2 clinical trial of 10XB-101 Solution for Injection, 6.0% in Subcutaneous Fat Disorder, sponsored by 10xBio, LLC.

Who is sponsoring NCT05760248?

NCT05760248 is sponsored by 10xBio, LLC.

What drugs are being tested in NCT05760248?

Interventions in NCT05760248: 10XB-101 Solution for Injection, 6.0%, Placebo Solution for Injection (no active ingredient).

What condition does NCT05760248 study?

NCT05760248 studies Subcutaneous Fat Disorder.

Is NCT05760248 still recruiting?

NCT05760248 is currently completed. Last updated 29 June 2025.

Last reviewed 2025-06-29 · How we verify

NCT05760248

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

Completed Phase 2 Last updated 29 June 2025

What this trial tests

Phase 2 trial testing 10XB-101 Solution for Injection, 6.0% in Subcutaneous Fat Disorder in 13 participants. Completed in 22 January 2025.

Timeline

4 May 2023

Primary endpoint
22 January 2025

22 January 2025

Quick facts

Lead sponsor	10xBio, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	13
Start date	4 May 2023
Primary completion	22 January 2025
Estimated completion	22 January 2025
Sites	2 locations across United States

Drugs / interventions tested

10XB-101 Solution for Injection, 6.0% — full drug profile →
Placebo Solution for Injection (no active ingredient) — full drug profile →

Conditions studied

Subcutaneous Fat Disorder — all drugs for Subcutaneous Fat Disorder →

Sponsor

10xBio, LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Subcutaneous Fat Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Participants will be: * Be given injections every month for 5 months over the right and left flanks. * Be asked to be seen in the clinic for 13 visits and 3 phone call visits during a duration of 1 year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other 10xBio, LLC trials

Trials by the same sponsor.

NCT05154955 — A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat · Phase 2 · completed
NCT04258761 — A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin") · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05760248 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 10xBio, LLC
Last refreshed: 29 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05760248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing